How are regulatory changes affecting early stage R&D in China?

December 6, 2016 Christoph Graener

Darren Ji, former VP and global head of Asia and emerging markets at Roche, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about current trends disrupting the pharma sector in China.
Darren Ji took part in a panel at BIO-Europe® 2016 focused on changes in the Chinese pharma industry. He discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes for early stage R&D in the region.

  

  

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Darren Ji – Former VP, Global Head, Asia and Emerging Markets, Partnering, Roche

Previous Article
Dimerix CEO explains company’s different drug combo R&D strategy
Dimerix CEO explains company’s different drug combo R&D strategy

Kathy Harrison, CEO of Australian biotech Dimerix, talks about the company's unusual business model, Dimeri...

Next Article
Denali deal and F-star’s innovative asset centric business model
Denali deal and F-star’s innovative asset centric business model

Jane Dancer, chief business officer at F-star, discusses F-star's asset-centric business strategy and the c...